Company: BFRG
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023496
Chunk: 7

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 7
---
 (126,191) 
     (389,880)
  
    Net cash provided by financing activities 
     996,999  
     5,952,472 

    Net (decrease) increase in cash and cash equivalents 
     (3,340,271) 
     1,614,258 

    Cash and cash equivalents, beginning of period 
     5,435,983  
     2,624,730 
  
    Cash and cash equivalents, end of period 
    $2,095,712  
    $4,238,988 

    Supplemental cash flow information: 

    Cash paid for interest 
    $5,007  
    $16,150 
  
    Cash paid for taxes 
    $-  
    $- 

    Supplemental disclosures of noncash investing and financing activities 

    Issuance of common stock as commitment fee in advance of equity transaction 
    $207,493  
    $- 

See
accompanying notes to unaudited condensed consolidated financial statements.

5

BullFrog
AI Holdings, Inc.

Notes
to Condensed Consolidated Financial Statements (Unaudited)

1.Organization
                                            and Nature of Business

Description
of Business

BullFrog
AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February
6, 2020. BullFrog AI Holdings, Inc. is the parent company of BullFrog AI, Inc. and BullFrog AI Management, LLC, which were incorporated
in Delaware and Maryland, in 2017 and 2021, respectively. All the Company’s operations are currently conducted through BullFrog
AI Holdings, Inc., which began operations on February 6, 2020. The Company is focused specifically on advanced artificial intelligence
and machine learning (“AI/ML”) driven analysis of complex data sets in medicine and healthcare. The Company’s objective
is to utilize its AI/ML platform to provide a precision medicine approach to drug asset enablement through external partnerships and
selective internal development.

Most
new therapeutics will fail at some point in preclinical or clinical development. These failures are the primary drivers for the high
cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex
and highly dimensional data generated at each stage of development to de-risk subsequent